Literature DB >> 22983586

Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.

Fiorina Giona, Stefania Mariani, Lucio Gnessi, Maria Luisa Moleti, Massimiliano Rea, Annalisa De Vellis, Deborah Marzella, Anna Maria Testi, Robin Foà.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22983586      PMCID： PMC3659938          DOI： 10.3324/haematol.2012.067447

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.

Authors:  Stefania Mariani; Fiorina Giona; Sabrina Basciani; Marina Brama; Lucio Gnessi
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

2.  Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.

Authors:  Sofia Jönsson; Bob Olsson; Claes Ohlsson; Mattias Lorentzon; Dan Mellström; Hans Wadenvik
Journal:  Haematologica       Date:  2008-05-27       Impact factor: 9.941

3.  Altered bone and mineral metabolism in patients receiving imatinib mesylate.

Authors:  Ellin Berman; Maria Nicolaides; Robert G Maki; Martin Fleisher; Suzanne Chanel; Kelly Scheu; Bri-Anne Wilson; Glenn Heller; Nicholas P Sauter
Journal:  N Engl J Med       Date:  2006-05-11       Impact factor: 91.245

4.  Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.

Authors:  Susan L Hobernicht; Bahareh Schweiger; Philip Zeitler; Michael Wang; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2010-12-22       Impact factor: 3.167

5.  Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats.

Authors:  Mirja Nurmio; Henna Joki; Jenny Kallio; Jorma A Määttä; H Kalervo Väänänen; Jorma Toppari; Kirsi Jahnukainen; Tiina Laitala-Leinonen
Journal:  Toxicol Appl Pharmacol       Date:  2011-05-04       Impact factor: 4.219

6.  Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.

Authors:  Haruko Shima; Mika Tokuyama; Akihiko Tanizawa; Chikako Tono; Kazuko Hamamoto; Hideki Muramatsu; Akihiro Watanabe; Noriko Hotta; Masaki Ito; Hidemitsu Kurosawa; Koji Kato; Masahito Tsurusawa; Keizo Horibe; Hiroyuki Shimada
Journal:  J Pediatr       Date:  2011-05-17       Impact factor: 4.406

7.  Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.

Authors:  Birgit Geoerger; Bruce Morland; Anna Ndiaye; Francois Doz; Gabriel Kalifa; Anne Geoffray; Fabienne Pichon; Didier Frappaz; Etienne Chatelut; Paule Opolon; Sharon Hain; Francoise Boderet; Jacques Bosq; Jean-Francois Emile; Marie-Cecile Le Deley; Renaud Capdeville; Gilles Vassal
Journal:  Eur J Cancer       Date:  2009-04-09       Impact factor: 9.162

8.  Long-term imatinib therapy promotes bone formation in CML patients.

Authors:  Stephen Fitter; Andrea L Dewar; Panagiota Kostakis; L Bik To; Timothy P Hughes; Marion M Roberts; Kevin Lynch; Barrie Vernon-Roberts; Andrew C W Zannettino
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

9.  Gynaecomastia in men with chronic myeloid leukaemia after imatinib.

Authors:  Carlo Gambacorti-Passerini; Lucia Tornaghi; Francesco Cavagnini; Pellegrino Rossi; Francesca Pecori-Giraldi; Luigi Mariani; Nadia Cambiaghi; Enrico Pogliani; Gianmarco Corneo; Lucio Gnessi
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

10.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Authors:  H Jean Khoury; Jorge E Cortes; Hagop M Kantarjian; Carlo Gambacorti-Passerini; Michele Baccarani; Dong-Wook Kim; Andrey Zaritskey; Athena Countouriotis; Nadine Besson; Eric Leip; Virginia Kelly; Tim H Brümmendorf
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113
View more
  15 in total

1.  Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.

Authors:  Rick Proschmann; Christoph Baldow; Tino Rothe; Meinolf Suttorp; Christian Thiede; Josephine T Tauer; Martin C Müller; Andreas Hochhaus; Ingo Roeder; Ingmar Glauche
Journal:  Haematologica       Date:  2016-11-17       Impact factor: 9.941

Review 2.  Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Lauren Caldemeyer; Michael Dugan; John Edwards; Luke Akard
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

3.  Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

Authors:  Nobuko Hijiya; Kirk R Schultz; Markus Metzler; Frederic Millot; Meinolf Suttorp
Journal:  Blood       Date:  2015-10-28       Impact factor: 22.113

Review 4.  The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Authors:  A John Barrett; Sawa Ito
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

5.  Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.

Authors:  Yuli Cai; Chao Liu; Ye Guo; Xiaojuan Chen; Li Zhang; Yumei Chen; Yao Zou; Wenyu Yang; Xiaofan Zhu
Journal:  Int J Hematol       Date:  2021-01-01       Impact factor: 2.490

6.  Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.

Authors:  Sonali Chaudhury; Rodney Sparapani; Zhen-Huan Hu; Taiga Nishihori; Hisham Abdel-Azim; Adriana Malone; Richard Olsson; Mehdi Hamadani; Andrew Daly; Ulrike Bacher; Baldeep M Wirk; Rammurti T Kamble; Robert P Gale; William A Wood; Gregory Hale; Peter H Wiernik; Shahrukh K Hashmi; David Marks; Celalettin Ustun; Reinhold Munker; Bipin N Savani; Edwin Alyea; Uday Popat; Ronald Sobecks; Matt Kalaycio; Richard Maziarz; Nobuko Hijiya; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-08       Impact factor: 5.742

Review 7.  Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

Authors:  Deepam Pushpam; Sameer Bakhshi
Journal:  Daru       Date:  2020-01-03       Impact factor: 3.117

8.  Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Authors:  Nobuko Hijiya; Alexey Maschan; Carmelo Rizzari; Hiroyuki Shimada; Carlo Dufour; Hiroaki Goto; Hyoung Jin Kang; Terri Guinipero; Zeynep Karakas; Francisco Bautista; Stéphane Ducassou; Keon Hee Yoo; Christian Michel Zwaan; Frédéric Millot; Paola Aimone; Alex Allepuz; Sara Quenet; Florence Hourcade-Potelleret; Sabine Hertle; Darintr Sosothikul
Journal:  Blood       Date:  2019-12-05       Impact factor: 22.113

9.  Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats.

Authors:  Josephine T Tauer; Lorenz C Hofbauer; Roland Jung; Sebastian Gerdes; Ingmar Glauche; Reinhold G Erben; Meinolf Suttorp
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.